Optimal Strategies for Managing Adverse Events with GPRC5D Bispecifics in Multiple Myeloma
A panel of experts on multiple myeloma have a comprehensive discussion on the monitoring and management of adverse effects associated with GPRC5D therapy.
EP. 1: Long-Term Follow-up Overview: MajesTEC-1 and MagnetisMM-3 Recent Data
A panel of experts on multiple myeloma discuss long-term follow-up data from the MajesTEC-1 and MagnetisMM-3 clinical trials.
EP. 2: Adverse Event Management with BCMA Therapy
Ellen Marin, PA-C, provides an overview of adverse effects associated with BCMA-directed bispecific therapy in multiple myeloma.
EP. 3: GPRC5D Therapy: Unique Challenges in Adverse Event Management
Lisa Hwa, APRN, DNP, CNP, FAPO, describes the unique challenges in managing adverse events associated with GPRC5D therapy compared with other bispecifics.
EP. 4: Overview of Long-term Follow-up from MonumenTAL-1
Focusing on the MonumenTAL-1 study, Mary Steinbach, APRN, provides clinical insights on nail, skin, and oral toxicities associated with talquetamab.
